Background {#Sec1}
==========

In 2013, more than 12,800 patients with rare cancer received expert medical care in the framework of the French National Networks for Rare Cancers in Adults. Among these, 99 cases involved gestational, or pregnancy-associated cancers (PAC) \[[@CR1]\]. PAC are rare cancers defined as the occurrence of cancer during pregnancy or within 12 months after delivery. PAC management requires epidemiological evaluation of the pathways of care of these patients, especially as regards the specificities of diagnosis and therapeutic management. The physiological changes during pregnancy can also make diagnosis difficult. Furthermore, treatment of PAC is challenging, with a complex balance required between maternal well-being and the health of the unborn child.

In Martinique (French West-Indies), cancer is the second cause of mortality among females \[[@CR2]\]. Developing management of rare cancers in France is a major focus of the 2014--2019 National Cancer Plan. The International Network on Cancer, Infertility and Pregnancy (INCIP) also participates in cancer research in pregnancy to improve the state of knowledge among health professionals and patients.

Few data are available regarding PAC in the Caribbean. This study provides epidemiological data that give a clear description of maternal and neonatal outcomes during the 15-year study period.

Methods {#Sec2}
=======

We performed a retrospective study including all women diagnosed with PAC \[cancer diagnosed during pregnancy or within 1 year after delivery\] between 1st January 2000 and 31st December 2014 in the University Hospital of Martinique.

PAC cases were identified from Departments of Medical Information according to the International Classification of Disease codes for cancer cross-referenced with codes for pregnancy \[[@CR3]\]. Data quality controls performed by the Martinique Cancer Registry enabled validation of all cancer cases. All socio-demographic and clinical data were obtained by consulting medical records in hospital archives.

For each case, socio-demographic (age, marital status, professional activity, familial risk of cancer and comorbidities) and clinical variables (gravidity, parity, term at diagnosis, mode of cancer detection, symptoms, histology of tumor, grade of differentiation, treatment characteristics, pregnancy outcome, neonatal outcome and vital status of the mother) were recorded. Vital status cut-off date was May 21st, 2015. The international TNM Classification was used for cancer staging at diagnosis. This observational study was also based on data from the Martinique Cancer Registry for exhaustiveness of cancer cases. As regards the procedures for cancer registries, all patients are informed by medical doctors and the cancer Registry that cancer cases are recorded in the database of the Registry. This study was also registered with the French national commission for the protection of privacy and personal data (Commission Nationale Informatique et Libertés, CNIL). The Martinique Cancer Registry also participates in the national programme for epidemiological surveillance of cancer in France, under the auspices of the French network of general and specialised cancer registries (FRANCIM). Cancer cases were recorded in strict conformity with the international standards laid down by the International Agency for Research on Cancer (IARC), the French FRANCIM network, and the European Network of Cancer Registries (ENCR). Vital status of patients was obtained from the birth, deaths and marriages registry of each patient's place of birth up to June 17, 2015. Patient characteristics were described as median or means with standard deviations (SD) for quantitative variables, and as number (percentage) for qualitative variables. Incidence rate was calculated, and the population of pregnant women in the study region during the study period was used as the denominator, i.e. between 2000 and 2014, approximately 112,527 pregnancies in Martinique (total of deliveries and abortions). All analyses were performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec3}
=======

A total of 18 cases were included in this study. The most frequent tumor sites were gynecologic cancers (12 cases, 66.7%): 6 women were diagnosed with breast cancer (33.3%), 3 with ovarian cancer (16.7%) and 3 with cervical cancer (16.7%). Other cases were lymphoma (*n* = 1), brain cancer (*n* = 1), liver cancer (*n* = 1), colorectal cancer (*n* = 1), and skin cancer of the face (*n* = 1). In one case, the primary site was unknown. In our study, the estimated raw incidence of PAC was 0.16/1000 pregnancies during the period 2000--2014. By site, incidence is 0.05/1000 pregnancies for breast cancer and 0.03/ 1000 pregnancies for respectively cervical and ovarian cancer.

Mean age at the time of diagnosis was 35.7 ± 5.4 years, median age was 37.0 years \[range 26--44 years\]. Table [1](#Tab1){ref-type="table"} shows the socio-demographic profile of patients with PAC. In 17 cases (94.4%), the diagnosis was made during pregnancy. Only one woman was diagnosed during the post-partum period. Table [2](#Tab2){ref-type="table"} presents the diagnosis and therapeutic management data.Table 1Sociodemographic profile of 18 patients diagnosed with pregnancy-associated cancers between 1 January 2000 and 31 December 2014 in MartiniqueVariablesN%Age (years)\< 250-- \[25--29\]316.67 \[30--34\]211.11 \[35--39\]950.00\> 40422.22Gravidity\* 1316.67 2--31055.55\>3527.78Parity 0316.67 1--21266.66\>2316.67Marital status Single422.22 Married1055.56 Other422.22BMI\*\* Underweight \[10--19\]531.25 Normal \[20--24\]318.75 Overweight \[25--29\]318.75 Obesity \[29--80\]531.25 Unknown2Profession Professionally active1173.33 No professional activity426.67 Unknown3Familial risk of cancer Yes422.22 Unknown1477.78\**Gravidity includes the current pregnancy*\*\**BMI Body Mass Index* Table 2Tumor characteristics, clinical profile, characteristics of diagnosis and therapeutic managementCase numberTumor siteHistologyAge, yGravidityParityComorbidityTerm at diagnosisMode of detectionType of symptomTNMDiagnosis basisTherapeutic approach1Breast cancer[Infiltrating duct adenocarcinoma](http://codes.iarc.fr/code/2992)3232High blood pressureT1SymptomsBreast tumefactionT4N2M1HP--2Breast cancerCarcinoma3521--T1SymptomsAdenopathyTXN1cM0HMCT^a^3Breast cancerInfiltrating duct carcinoma3954--T3SymptomsMotor deficitT4N3M1HPRT/CT/HT4Breast cancerInfiltrating duct carcinoma4064--T2SymptomsBreast tumefactionT1cN0M0HPSG/CT5Breast cancerInfiltrating duct adenocarcinoma4332--T3SymptomsBreast tumefactionT4N1M0HPCT6Breast cancerInfiltrating duct carcinoma4421--T3SymptomsBreast tumefactionT2N0M0HPSG7Cervical cancerSquamous intraepithelial neoplasia2810Gestational diabetesT2Screening--T1N0M0HPSG^a^8Cervical cancerSquamous intraepithelial neoplasia3832--T1Screening--T1N0M0HPSG9Cervical cancerInvasive adenocarcinoma3964High blood pressureT1SymptomsEndocol polypT2N0M0HPSG^a^/CT-RT/BT10Ovarian cancerImmature malignant teratoma2621Cardiac AbnormalityT3SymptomsOvarian massT2aN0M0HPSG^a^/CT11Ovarian cancerDysgerminoma2631--T1Fortuitous--T1cN0M0HPSG/CT12Ovarian cancerUndifferentiated sarcoma3742--Day 2 PPSymptomsSevere pain in pelvixT3cNXM1HPSG/CT13HTLV LymphomaT-cell large granular lymphocytic leukemia3010Polytrauma ChronicT3Fortuitous----Cytology--14Liver cancerCholangiocarcinoma4151--T2Fortuitous--T4N1M1Clinic and paraclinic--15Face skin cancerNaso-sinusal malignant melanoma3631--T3SymptomsBlindnessT4N0M1HPCT16Colorectal cancerNeoplasm malignant3531--T2SymptomsAnemiaTXNXM1HM--17Brain cancerMeningothelial meningioma3710--T1SymptomsAdenopathyM0HP--18Unknown primitive siteAdenocarcinoma3731High blood pressureT3SymptomsMotor paraplegiaTXNXM1HMSG/ RT/HT*BT* brachytherapy, *CT* chemotherapy, *HM* histology on metastasis, *HP* histology on primitive, *HT* hormone therapy, *RT* radiotherapy, *SG* surgery^a^Treatment during pregnancy

In most cases, PAC was detected in symptomatic individuals (72.2%). In three cases, the detection of cancer was fortuitous and in three other cases, cancer was detected after screening tests. In this study, only one case was multifocal, while seven women had metastases in various sites. Nine women (50.0%) had nodal involvement or initial metastases at the time of diagnosis.

As regards management of PAC, four pregnant women (*cases 2--7--9-10*) received oncological treatment (three were treated by surgery and one by chemotherapy). Among these, only two carried their pregnancy to live birth (*cases 7 and 10*). Eleven women started treatment during the post-partum period and three women died before treatment could be initiated.

In all, 11 pregnancies resulted in a live birth. One woman presented a twin pregnancy associated with cancer. Maternal and neonatal outcomes are presented in Table [3](#Tab3){ref-type="table"}. All cases of caesarean sections before labor, medical termination of pregnancy and voluntary induced abortion (9/18) were motivated by the diagnosis of cancer. Overall, 12 live births from a total of 11 pregnancies (61.1% of PAC) were recorded, with satisfactory APGAR (3 unknown). Seven fetal losses were identified (38.9% of PAC). Mean weight at live birth was 2.7 kg ± 637 g. The rate of preterm birth was 58.3% (7/12 deliveries). Prematurity was spontaneous for two cases and five cases were induced for "therapeutic reasons related to cancer". The main neonatal outcome observed was prematurity, with six cases of late preterm (34 -- 36 weeks and 6 days) and one case of very preterm birth (28 weeks). No other pediatric pathology was described. No child was born after chemotherapy in utero. Six maternal deaths occurred during the study period. The time between diagnosis and death ranged from 9 days to 2 years.Table 3Pregnancy, maternal and neonatal outcomesCaseTumor sitePregnancy outcomeNeonatal outcomeMaternal follow-upTerm at delivery, wBeginning of laborOutcome of pregnancyFetal weightAPGAR1/5 minVital statusTime diagnosis-death,d1Breast cancer14InductionMTP----Dead92Breast cancer18InductionMTP250--Unknown--3Breast cancer34CSBLLive birthUnknownUnknownDead6774Breast cancer20InductionMTP335--Alive--5Breast cancer35CSBLLive birth268010/10Alive--6Breast cancer38InductionLive birth249010/10Alive--7Cervical cancer36SpontaneousLive birth315010/10Alive--8Cervical cancer6InductionVIA----Alive--9Cervical cancer12SpontaneousSM----Alive--10Ovarian cancer36CSBLLive birth254010/10Alive--11Ovarian cancer6SpontaneousSM----Alive--12Ovarian cancer36SpontaneousLive birth277510/10Dead2413HTLV Lymphoma39InductionLive birth379510/10Unknown--14Liver cancer21SpontaneousSM260--Dead3015Face skin cancer35CSBLLive birth26506/10Dead33116Colorectal cancer28CSBLLive birth13908/9Dead5317Brain cancer41InductionLive birth292510/10Alive--18Unknown primitive siteUnknownUnknownLive birth\*2Unknown\*2Unknown\*2Unknown--*CSBL* caesarean section before labor, *d*, days, *min*, minutes, *MTP* medical termination of pregnancy, *SM* spontaneous miscarriage, VIA voluntary induced abortion, *w* weeks

All cases in our study were discussed in cancer staff meetings, and management was discussed with a multidisciplinary team comprising oncologists and gynecologist-obstetricians. Three women received support from a social worker, and 8 women had a consultation with psychologist. Five patients requested expert advice or a second opinion from reference centers in mainland France. The rate of medical transfers organized at the request of professionals was 3/18 (16.6%).

Discussion {#Sec4}
==========

Our study is an overview of PAC management in Martinique.

With 12.3 births per 1000 inhabitants in Martinique, our birth rate is close to the national rate (12.8 per 1000 inhabitants) in 2010. Almost 25% children born in Martinique in 2010 had a mother aged 35 years or more (21.5% of births at a national level). Ten years ago, the respective rates were 19% in Martinique and 16.5% in France \[[@CR4]\]. The increasing incidence of PAC is therefore likely due to the older age at which women become pregnant \[[@CR5]\]. In the study period \[2000--2014\], we found 18 women between 26--44 years diagnosed with PAC; with a median age of 37.

In our study, pregnancy-associated-cancer affects approximately 1 in 6250 pregnancies. It is estimated in the literature that cancer complicates between 1/1000 pregnancies and 1/6000 pregnancies \[[@CR6]--[@CR8]\], with the most common malignancies diagnosed during pregnancy being gynecological cancer \[[@CR9], [@CR10]\]. Breast cancer is known to be one of the most common cancers occurring during pregnancy (3000--10,000 pregnancies annually) \[[@CR11]\]. In Martinique, this is the first cancer site in terms of incidence and mortality \[[@CR2]\], and the most common site of PAC in our study.

Ovarian masses complicate pregnancy with an overall incidence of 2.4--5.7% \[[@CR9]\]. Grimm et al. \[[@CR9]\] even reported a higher incidence, probably explained by more frequent detection thanks to the wider use of ultrasound as a routine antenatal evaluation technique. The asymptomatic character of ovarian cancer makes early diagnosis difficult \[[@CR12]\]. Ovarian cancers and cervical cancers were joint second most common in terms of frequency in our study (*n* = 3 for each).

Cervical cancers in women are more frequent in the Caribbean, especially in young women \[[@CR2]\]. A recent study conducted in Martinique to describe the epidemiology and survival of cervical cancer based on data from the Martinique cancer registry could be informative for PAC management.

A survey of clinical practices performed by Han et al. showed important differences between physicians in the approach to PAC management \[[@CR13]\]. These authors reported that non-academic hospitals tended to prefer termination of pregnancy and refraining from treatment during pregnancy, while, in parallel, academic hospitals had an increased tendency to consider treatment during pregnancy \[[@CR13]\]. Interestingly, our results come from a regional university hospital, but correspond to what Han et al. reported to be the preferred strategy for "non-academic centers", in that we also observed that chemotherapy was not performed in pregnant women and terminations of pregnancy were the preferred option. As yet, there not appear to be a clear move towards a policy of considering the possibility of oncological treatments during pregnancy. According to Kirby \[[@CR14]\], "the biggest challenge is educating the public that chemotherapy is possible in pregnancy without harm for the baby." The literature contains various reports of women who received chemotherapy during pregnancy and who went on to give birth to healthy babies without congenital malformations \[[@CR12], [@CR15], [@CR16]\]. In our study, chemotherapy was not the first choice treatment modality for PAC. Only two cases of pregnancies that carried to term underwent surgery during gestation.

In our study, 4 cases (22.2%) of abortion (voluntary or medical) were mentioned with maternal cancer as the motive. For invasive cancer, Van Calsteren and al \[[@CR10]\] described the outcomes of 215 cases of PAC and reported 30 cases (14.0%) of pregnancy terminations, with the main indication (29/30) being the maternal malignancy. Several studies have shown that interruption of pregnancy does not improve maternal prognosis but is indicated when cytotoxic treatment is an emergency in the first trimester \[[@CR14], [@CR17], [@CR18]\]. National and international guidelines have been published for the management of several sites of PAC \[[@CR5]\] \[[@CR19], [@CR20]\]. However, in the absence of large randomized trials, it is difficult to know how best to manage these women. Each case needs to be addressed individually, and should be discussed case-by-case, taking into account the term of the pregnancy, the patient's wishes and the tumor stage. In Martinique, multidisciplinary cancer staff meetings bring together oncologists and obstetric gynecologists. Neonatologists, onco-psychiatrists and social workers can be invited to participate in these meetings with a view to better management of PAC. Ferrere and Wendland indicated that PAC is a situation that incurs a major risk of anxiety and depressive symptoms, and there is much to be gained from evaluation of psychopathological risks in this context \[[@CR21]\]. In our study, eight women had psychological consultations.

In most studies and reviews \[[@CR22]--[@CR24]\], PAC is considered to have an unfavorable prognosis due to delayed diagnosis and limitations in oncologic therapy. In our study, 9 women had nodal involvement or initial metastases at diagnosis. Any delay in treatment may unacceptably worsen the maternal prognosis. The major neonatal outcome in our series was preterm birth, with 58.3% of viable deliveries, and this rate is similar to another study \[[@CR10]\]. Indeed, Van Calsteren et al. \[[@CR10]\] concluded that prevention of iatrogenic prematurity appears to be an important part of the treatment strategy. The real incidence of PAC in Martinique is difficult to assess because of the lack of a specific PAC registry for exhaustive case collection. The existence in our study of only a single reported case of PAC during the postpartum period could suggest under-reporting of incident cases. The number of cases in our study is dependent on the quality of the coding of medical records. According to the study conducted by Han et al. \[[@CR13]\], 75% of European physicians interviewed were interested in registering patients anonymously in a centralized database. A Caribbean Observatory for Rare Cancers could collect and follow a larger number of PAC and other rare cancers. This observatory could constitute an inter-regional center of expertise for the French National Network for health professionals.

The French national PAC network ("Cancers Associés à la Grossesse") created in 2008 in Metropolitan France, under the auspices of the National College of Obstetricians and Gynecologists, is a platform for coordination and cooperation between clinical hospital units. It was created to optimize and homogenize care of patients throughout France. With an estimated incidence of 500 new cases per year in 2013, only 99 new cases had been registered, indicating a low coverage rate of 19.8% \[[@CR25]\]. The Caribbean Observatory for Rare Cancers could help in increasing this coverage rate.

Strengths and weaknesses of the study {#Sec5}
-------------------------------------

To the best of our knowledge, this is the first study to focus on maternal and neonatal outcomes after PAC in the French West-Indies (Martinique). In the Caribbean archipelago, few studies have been conducted on this topic to date \[[@CR26], [@CR27]\]. Our results can be considered as a representative sample of the target population in Martinique, since management of PAC is mainly organized in University Hospital of Martinique, and all cases of PAC were addressed to our university hospital referral centre for care. Cross-referencing of data from the Department of Medical Information with the data from the Cancer Registry, as well as examination of source medical files enabled us to exclude any cases not corresponding to cancers in pregnancy.

The main limitation of this cross-sectional study is the methodological difficulty in identifying patients for case collection, since case identification depends directly on the accuracy of the data extracted from medical informatics by the Department of Medical Information. In addition, there may be some selection bias due to patients living in Martinique who choose to travel elsewhere (in particular, to mainland France) for treatment, either for personal reasons or because they are encouraged to do so by their physician. However, these limits would likely lead to under-representation of the true number of cases, and therefore, underestimation of incidence.

The number of cases in our study also remains directly dependent on the quality of the coding of records by medical professionals. The high rate of transfers increases the proportion of missing data. The detection of a single case of PAC during the postpartum could suggest under-reporting of incident cases.

Conclusion {#Sec6}
==========

Collaboration with this national network could be helpful for the organization of patient transfers to metropolitan France and post-transfer monitoring. Cancer management during pregnancy is a challenge for the French West Indies territories. Close cooperation with the International Network on Cancer, Infertility and Pregnancy could help to promote PAC research.
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